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radiotherapy(CIRT) for Oligo-metastatic tumors located 
different organ from various cancer. 
 
Material and Methods: From December 2009 to June 2013, 
17 patients joined into the clinical study as volunteers. The 
patients were not surgical candidates for medical reasons or 
patient refusal. The Oligometastases located in lung,brain 
and liver respectively from various cancer were treated with 
CIRT.The heavy ion beams energy was 230~350Mev / u and 
RBE value was 2.5. A median dose of 60 GyE (range, 20–66 
GyE) was delivered to the planning target volume (PTV) in 4-
12 fractions with a median daily dose of 5 GyE (range, 4.68–
5.5 GyE). Short-term effect was evaluated by tumor change 
in three months after treatment with RESIST criteria and 
adverse reactions were determined by criteria of acute 
radiation injury from Radiation Therapy Oncology Group. 
Treatment outcome was analyzed in terms of local control 
rate(LCR), survival rate. 
 
Results: In total, 17 patients (7 lung Oligometastases, 3 liver 
Oligometastases and 7 brain Oligometastases)with 17 Oligo-
metastatic lesions were treated with CIRT. Until December 
2014, median follow-up period was 18 months(2-40ms). 
Objective response rate was 94.1% to evaluate short-term 
effect (3CR, 10PR, 3NC, 1PD) .The 1-year LCR and overall 
survival of the treated patients were 93.3% and 51.0%. Only 1 
lung Oligometastases patients relapsed in 7 months after 
treatment. 1-year Survival rate were 47.6%,66.7%, 75% 
respectively in brain, lung and liver Oligometastases. Survival 
rate and LCR were not significantly correlated with 
Oligometastases location. All treatment-related 
complications were acute skin reaction and self-limited, 
without any grade 4–5 toxicity. 
 
Conclusion: ompared with Conventional radiotherapy, CIRT 
has short treatment time, high Biological effect advantages. 
CIRT may be one of effective, the least invasive and safe 
approach to patients with Oligometastases. 
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Purpose or Objective: This study summarizes the experience 
with carbon ion radiation therapy (RT) at the Heavy Ion 
Research Facility in Lanzhou since 2009. 
 
Material and Methods: From December 2009 to June 2013, 
60 patients joined into the clinical study as volunteers. 14 
patients with brain tumor〔cerebral glioma(n=6), metastatic 
brain tumor (n=8)〕,8 patients with head and neck tumor,15 
patients with chest tumor〔primary lung cancer (n=8), 
metastatic mediastinal carcinoma(n=1), metastatic lung 
cancer(n=6)〕,13 patients with abdominal 
carcinoma〔primary liver cancer(n=4), pancreatic 
cancer(n=1), abdominal soft tissue malignant tumor (n=3), 
metastatic liver cancer(n=4), abdominal lymph node 
metastasis carcinoma(n=1)〕,5 patients with pelvic 
tumor〔rectal cancer(n=1), anal cancer (n=1), ovarian 
carcinoma(n=1), chordoma(n=1), soft tissue tumor(n=1)〕,5 
patients with limbs tumor〔skin cancer(n=2), soft tissue 
malignant tumor(n=3)〕were treated with carbon ions beams. 
The beams energy was 230~350Mev / u and RBE value was 
2.5. A median dose of 60 GyE (range, 20–66 GyE) was 
delivered to the planning target volume (PTV) in 4-12 
fractions with a median daily dose of 5 GyE (range, 4.68–5.5 
GyE). Short-term effect was evaluated by tumor change in 
three months after treatment with RESIST criteria and 
adverse reactions were determined by criteria of acute 
radiation injury from Radiation Therapy Oncology Group. 
Treatment outcome was analyzed in terms of local control 
rate (LCR), survival rate. 
 
Results: Until December 2014, median follow-up period was 
18 months (2-40ms). Objective response rate was 98.3% to 
evaluate short-term effect (9CR, 37PR, 13NC, 1PD) .The 1-
year LCR and overall survival of the treated patients were 
80.2% and 62.8%. The local control and overall survival rates 
were not correlated with tumor location and pathological 
types, the main cause of death was distant metastasis. All 
treatment related complications were 1-2 grade acute skin 
reaction (incidence rate = 66.7%) and self-limited, without 
any grade 4–5 toxicity. 
 
Conclusion: Carbon ion therapy is safe with respect to 
toxicity , offers high tumor local control rates and 
significantly shorten the treatment time. But this study has 
limitations: a group of cancer patients in advanced stage and 
short survival and follow up time, small sample size and high 
heterogeneity because of tumor location, clinical stage and 
pathological type. More homogeneous prospective data, large 
multicentric and randomized trials are needed to evaluate 
the efficacy of heavy ion tumor therapy. 
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Purpose or Objective: Although radiation therapy (RT) is 
widely used in orbital tumors, the clinical use of ophthalmic 
RT has not been established in the lack of prospective data. 
This study evaluated the single institution’s patterns of care 
and treatment outcomes of RT in non-metastatic primary 
tumors and inflammatory diseases in the eye and orbit. 
 
Material and Methods: We retrospectively reviewed a total 
of 138 patients and 147 treatments of primary orbital 
malignancies or inflammatory conditions from January 2000 
to December 2013. The aims of RT consisted of definitive 
(n=121), postoperative (n=16), palliative (n=6), and salvage 
(n=4) treatment. Retrobulbar (34%) and conjunctival (22%) 
area were the common subsites of treatment. The median 
external beam RT dose was 30.6 Gy (range, 10.0-66.6) with a 
daily fraction size ranging from 1.7 to 4.0 Gy. Three-
dimensional conformal and intensity-modulated techniques 
were delivered in 67 (46%) and 5 (3%) treatments, 
respectively. 
 
Results: Forty-eight (35%) patients had benign inflammatory 
diseases including thyroid-associated ophthalmopathy (n=24), 
inflammatory pseudotumor (n=13), and choroidal neovascular 
membranes (n=11). In 90 (65%) patients with malignant 
tumors, 13 (9%) patients were children diagnosed with 
retinoblastoma (n=7), optic glioma (n=4), optic meningioma 
(n=1), and ocular teratoid medulloepithelioma (n=1). The 
other 77 (56%) patients were adult with the 5-year overall 
survival rate of 78.3%. Among the non-pediatric patients, 
mucosa-associated lymphoid tissue (MALT) lymphoma (n=36) 
was the most frequent disease entity, and the others also 
included optic meningioma (n=6), melanoma (n=5), and 
adenoid cystic carcinoma (n=5). In a total of 81 adult 
malignant tumors, complete and partial responses were 
observed in 67 (83%) tumors, and the patients’ 5-year 
relapse-free survival was 60.8%. In the 42 treatments of TAO 
and inflammatory pseudotumor, inflammatory symptoms 
were improved in 57%. There were 58 (39%) events of acute 
toxicities, and grade 1-2 ocular discomfort (n=18) and nausea 
(n=9) were frequent. Among the 24 (16%) events of late 
toxicities, 10 (42%) and 2 (8%) events of radiation-induced 
cataract and retinopathy were observed, respectively. Grade 
≥3 toxicities were not reported. 
 
Conclusion: In current practices, the ophthalmic RT achieved 
an excellent treatment response and tumor control with 
tolerable short-term and long-term toxicities. Further 
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analysis with more advanced RT technique is needed to 
assess the future role of RT in orbital tumors. 
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Purpose or Objective: Breast cancer patients receiving post-
operative radiotherapy (RT) experience adverse effects and 
general fatigue is one of them. Although it is often not severe 
enough to interrupt the course of RT, it negatively affects 
quality of life. Some Japanese herbal medicines such as TJ-41 
(Hochu-ekki-to) are effective for fatigue and are often used 
in daily practice. The purpose of this study is to assess 
radiation-induced fatigue (RIF) in detail and investigate the 
effect of Japanese herbal medicine. 
 
Material and Methods: Breast cancer patients who received 
post-operative RT and agreed to answer a patient self-
reporting questionnaire (FACIT-F; Functional Assessment of 
Chronic Illness Therapy) were eligible for this study. We 
excluded patients who were receiving chemotherapy 
concurrently. RIF was defined as fatigue which occurred 
during the period of radiotherapy and there were no causes 
for the fatigue other than the radiotherapy. The FACIT-F 
questionnaire was answered before RT, at one week after the 
beginning of RT, at the end of RT and one month after the 
end of RT. We prescribed TJ-41 to the RIF patients during the 
radiotherapy. We defined as responders the patients who 
experienced improvements in RIF and hoped for further 
prescription. 
 
Results: Fifty-two patients were enrolled for this study. RIF 
was observed in 24 (46 %) patients. On univariate analysis, 
the statistically significant predictor of RIF was the score of 
FACIT-F before RT. TJ-41 was administered to 9 patients and 
8 of them (89 %) were responders. 
 
Conclusion: RIF was common in breast cancer patients 
receiving post-operative RT and TJ-41 was effective for the 
RIF patients and improved their quality of life. However, 
these results may lack objectivity and the study was 
conducted with no placebo group. Improvement in objectivity 
of the assessment and a comparative study will be needed. 
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Purpose or Objective: Hyperthermia is a powerful 
radiosensitizer for treatment of superficial tumors. Several 
trials showed an advantage of combining radiotherapy with 
hyperthermia in terms of both local tumor control and overall 
survival. The purpose of this study is to evaluate both 
efficacy and toxicity of radiotherapy-hyperthermia (RT-HT) in 
the treatment of superficial recurrent and metastatic tumors 
in patients previously or not previously irradiated. 
 
Material and Methods: In our Institution twenty-three 
patients (mean age 71,4 years; range: 51-88) with 
histologically confirmed superficial recurrent/metastatic 
tumors were enrolled: 11 breast carcinoma, 6 head&neck 
cancer, 2 malignant melanoma, 2 sarcomas, 1 uterine 
adenocarcinoma and 1 hepatocarcinoma. Patients underwent 
radiotherapy treatment using 3D-conformal radiotherapy 
(8/23) or Helical Tomotherapy (15/23). External beam 
radiotherapy was delivered in 6-27 fractions of 1.8-5 Gy for a 
total dose of 20-57.5 Gy (mean external dose: 41 Gy). 
Prescribed dose was established taken into account, of the 
previous radiation doses, in previously irradiated patients, 
Karnofsky performance status and patient compliance. 
Hyperthermia treatment was performed with an 
electromagnetic superficial applicator operating at the 
frequency of 434 MHz. HT session was delivered once/twice 
weekly during the period of external radiotherapy, 1-2 hours 
after radiotherapy, to a mean total of 5 treatments [range: 
1-9 sessions]. Termocouples were used to evaluate 
temperature distribution map. Average, maximum and 
minimum temperature parameters were recorded during 
hyperthermia treatment. The treatment goal was to reach 
40- 42°C in > 90% (T90) of measured points for a duration of 
60 minutes. Acute and late toxicity was evaluated according 
to the CTCAE criteria. Local control was assessed after the 
end of the treatment on the basis of the RECIST Criteria.  
 
Results: During hyperthermia treatment the median 
temperature reached was 40.5 °C [range: 39 – 42.9°C]. 
During the radiotherapy in association with hyperthermia 2 
pts (10%) had G3 toxicity and one of these interrupted the 
treatment. One pt had acute cutaneous toxicity ≥ G3 at 1 
month. No pts had toxicity ≥ G2 at 3 and 6 months. No 
toxicity was observed at 12 months. The mean follow-up was 
10 months (range 3-22 months). Four pts (17%) had a 
complete response (CR), 11 pts ( 48%) had a partial response 
(PR),7 pts (30%) had a stable disease, (SD) and only 1 pt (4%) 
had progression disease (PD) and subsequently died. The 
Local control rate was 95%. Univariate analysis showed that 
Tmean,Tmax, Tmin,T90 parameters were not associated with 
local control rate.  
 
Conclusion: Radio-hyperthermia can result in an effective 
approach, particularly in previously irradiated patients or in 
radio-resistant tumors. Our results show that Radio-
Hyperthermia is an useful combined treatment with a good 
local control rate and a very high patient compliance.  
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Purpose or Objective: The purpose of this study is to 
evaluate the decrease in pain of patients treated with low-
dose radiation therapy in osteoarthritis. 
 
Material and Methods: From April 2015 to September 2015, 
11 patients (10 female and 1 men) were treated with low 
dose radiotherapy for pain control. All patients were 
refractory to conventional therapy prior to irradiation.  
13 joints (6 bursitis and 7 arthrosis): 4 trochanteritis, 5 
knees, 1 left thumb rhizarthrosis, 2 metacarpophalangeal 
joint and 1 right epicondylitis were treated.  
The median age was 69 years (range 46-89) with a median 
follow-up period of 3 months (range 0-6). Painful status was 
measured by visual analogue scale (VAS), with a median pre-
treatment value of VAS= 7(range 4-9).  
The radiotherapy dose of 6 Gy was delivered in 6 alternate 
days fractions of 1 Gy per fraction. In those patient with no 
pain relive post-treatment with VAS of or above 6 a second 
course of radiotherapy was proposed.  
The second RT series started 8 weeks after the first RT 
series.  
 
Results: The analysis was performed before the treatment 
and at the last follow-up. With a median VAS = 5 (range 0-8) 
7 patients achieved pain relief, 3 patients underwent a 
second course of radiotherapy with identical dose, and 1 
patient showed no change in pain. Daily requirements of 
analgesic were removed of reduced in 5 patients, subjective 
pain perception of response to irradiation evaluated at time 
of last visit regarding pre-treatment status was considered as 
“better” by 73% of patient. No patients presented acute or 
late complications attribute to radiation therapy. 
